Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > EY sees bolt-ons in the single to double digit billions now

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 01, 2022 5:13pm

204 Views

Post# 35064508

RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now

Future ONCY annual earnings of US$8.5 per share equates to a company acquisition valuation of >US$ 8.0 Billion.

Easy peezy. Why accept less when the market is getting ready to move UP.

Furthermore, Immunomedics was acquired for US$21 Billion and doesn't have the Platform Technology that ONCY's pelareorep can provide.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China